A protocol for active surveillance of acute myocardial infarction in association with the use of a new antidiabetic pharmaceutical agent

Pharmacoepidemiology and Drug Safety

Volumn 21, Issue SUPPL. 1, 2012, Pages 282-290

  Fireman, Bruce ^a   Toh, Sengwee ^b   Butler, Melissa G ^c   Go, Alan S ^a   Joffe, Hylton V ^d   Graham, David J ^d   Nelson, Jennifer C ^e   Daniel, Gregory W ^f   Selby, Joe V ^a  

^a DIVISION OF RESEARCH   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c KAISER PERMANENTE   (United States)

^d CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^e CENTER FOR HEALTH STUDIES   (United States)

^f HEALTHCORE INC   (United States)

Author keywords

Acute myocardial infarction; Diabetes mellitus; Drug safety; Drug surveillance; Saxagliptin

Indexed keywords

GLIBENCLAMIDE; GLIMEPIRIDE; GLIPIZIDE; INSULIN; PIOGLITAZONE; SAXAGLIPTIN; SITAGLIPTIN; SULFONYLUREA;

ACUTE HEART INFARCTION; ARTICLE; BLOOD PRESSURE; CLINICAL PROTOCOL; DATA BASE; DRUG APPROVAL; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG USE; EXPERIENCE; FOOD AND DRUG ADMINISTRATION; HUMAN; MEDICAL DECISION MAKING; NON INSULIN DEPENDENT DIABETES MELLITUS; ORGANIZATION; POPULATION; PRIORITY JOURNAL; RISK; SCORING SYSTEM; SYSTEMATIC REVIEW;

ADAMANTANE; COHORT STUDIES; CONFOUNDING FACTORS (EPIDEMIOLOGY); DIPEPTIDES; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DRUG APPROVAL; FOLLOW-UP STUDIES; HUMANS; HYPOGLYCEMIC AGENTS; MYOCARDIAL INFARCTION; POISSON DISTRIBUTION; PRODUCT SURVEILLANCE, POSTMARKETING; PROPORTIONAL HAZARDS MODELS; REGRESSION ANALYSIS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84856066315     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.2337     Document Type: Article

References (29)

1. U.S. Food and Drug Administration. COX-2 Selective (includes Bextra, Celebrex, and Vioxx) and Non-Selective Non-Steroidal Anti-Inflammatory Drugs (NSAIDs). [14 September 2011].
2. U.S. Food and Drug Administration. FDA Drug Safety Communication: FDA Recommends Against the Continued Use of Meridia (sibutramine). [14 September 2011].
3. U.S. Food and Drug Administration. FDA significantly restricts access to the diabetes drug Avandia. [14 September 2011].
4. Center for Drug Evaluation and Research (CDER) U.S. Food and Drug Administration. Guidance for Industry: Diabetes Mellitus - Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes. U.S. Department of Health and Human Services. Bethesda, MD. [30 January 2011].
5. Frederich R, Alexander JH, Fiedorek FT, et al. A systematic assessment of cardiovascular outcomes in the saxagliptin drug development program for type 2 diabetes. Postgrad Med 2010; 122(3): 16-27.
6. Does saxagliption reduce the risk of cardiovascular events when used alone or added to other diabetes medications (SAVOR-TIMI 53). [14 September 2011].
7. Selby JV, Fireman B, Butler MG. Report to FDA on a protocol for active surveillance of acute myocardial infarction in association with use of a pharmaceutical agent. [14 September 2011].
8. Behrman RE, Benner JS, Brown JS, et al. Developing the Sentinel System - A National Resource for Evidence Development. N Engl J Med 2011; 364: 498-499.
9. Schneeweiss S. A basic study design for expedited safety signal evaluation based on electronic healthcare data. Pharmacoepidemiol Drug Saf 2010; 19: 858-868.
10. Ray WA. Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol 2003; 158: 915-920.
11. Curtis LH, Weiner MG, Boudreau DM, et al. Design and use of the Mini-Sentinel distributed database. Pharmacoepidemiol Drug Saf 2012; 21(S1): 23-31.
12. Cutrona S, Toh S, Iyer A, et al. Design for validation of acute myocardial infarction cases in Mini-Sentinel. Pharmacoepidemiol Drug Saf 2012; 21(S1): 274-281.
13. Graham DJ, Ouellet-Hellstrom R, MaCurdy TE, et al. Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone. JAMA 2010; 304: 411-418.
14. Kiyota Y, Schneeweiss S, Glynn RJ, et al. Accuracy of Medicare claims-based diagnosis of acute myocardial infarction: estimating positive predictive value on the basis of review of hospital records. Am Heart J 2004; 148(1): 99-104.
15. Rosenbaum P, Rubin D. The central role of the propensity score in observational studies for causal effects. Biometrika 1983; 70(1): 41-55.
16. Joffe MM, Rosenbaum PR. Invited commentary: propensity scores. Am J Epidemiol 1999; 150(4): 327-333.
17. Glynn RJ, Schneeweiss S, Sturmer T. Indications for propensity scores and review of their use in pharmacoepidemiology. Basic Clin Pharmacol Toxicol 2006; 98: 253-259.
18. Ray WA, Stein CM, Daugherty JR, Hall K, Arbogast PG, Griffin MR. COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease. Lancet 2002; 360: 1071-1073.
19. Arbogast PG, Ray WA. Use of disease risk scores in pharmacoepidemiologic studies. Stat Methods Med Res 2009; 18: 67-80.
20. Cadarette SM, Gagne JJ, Solomon DH, et al. Confounder summary scores when comparing the effects of multiple drug exposures. Pharmacoepidemiol Drug Saf 2010; 19: 2-9.
21. Rassen JA, Avorn J, Schneeweiss S. Multivariate-adjusted pharmacoepidemiologic analyses of confidential information pooled from multiple health care utilization databases. Pharmacoepidemiol Drug Saf 2010; 19: 848-857.
22. Parsons L. Reducing Bias in a Propensity Score Matched-Pair Sample Using Greedy Matching Techniques. Sas Users Group International Conference, Vol 214-26. SAS Institute Inc.: Long Beach, CA, 2001.
23. Fireman B, Lee J, Lewis N, et al. Influenza vaccination and mortality: differentiating vaccine effects from bias. Am J Epidemiol 2009; 170: 650-656.
24. DeMets DL, Lan KK. Interim analysis: the alpha spending function approach. Stat Med 1994; 13: 1341-1352; discussion 1353-1346.
25. Li L, Kulldorff M. A conditional maximized sequential probability ratio test for pharmacovigilance. Stat Med 2010; 29: 284-295.
26. Kuldorff M, Davis R, Kolczak M, et al. A maximized sequential probability ratio test for drug and vaccine safety surveillance. Seq Anal 2011; 30: 58-78
27. Pocock S. Group sequential methods in the design and analysis of clinical trials. Biometrika 1977; 64: 191-199.
28. O'Brien PC, Fleming TR. A Multiple Testing Procedure for Clinical Trials. Biometrics 1979; 35: 549-556.
29. Stürmer T, Rothman KJ, Avorn J, Glynn RJ. Treatment effects in the presence of unmeasured confounding: dealing with observations in the tails of the propensity score distribution--a simulation study. Am J Epidemiol 2010; 172: 843-854.